Defunct Company
Total Trials
3
As Lead Sponsor
As Collaborator
0
Total Enrollment
109
NCT03249740
A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration
Phase: Phase 1
Role: Lead Sponsor
Start: Aug 29, 2017
Completion: Jan 16, 2019
NCT04085341
A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion
Phase: Phase 2
Start: Sep 11, 2019
Completion: Jun 5, 2020
NCT03953079
A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD
Start: Sep 26, 2019
Completion: Jun 3, 2021